APTX - Aptinyx Inc.

Other OTC - Other OTC Delayed price. Currency in USD

Aptinyx Inc.

909 Davis Street
Suite 600
Evanston, IL 60201
United States
847 871 0377

Full-time employees12

Key executives

NameTitlePayExercisedYear born
Dr. Andrew D. Kidd B.M. B.Ch., M.D.Interim Principal Exec. Officer, Principal Financial Officer & Principal Accounting Officer736.6kN/A1976
Mr. Craig R. Jalbert CIRAPres, Treasurer, Corp. Sec. & DirectorN/AN/A1962
Mr. Patrick FlavinSr. Mang. of Corp. Devel. & Investor RelationsN/AN/AN/A
Ms. Molly DirVP of HRN/AN/AN/A
Dr. Kathryn King Ph.D.Sr. VP of Clinical & CMC OperationsN/AN/AN/A
Mr. Tim NoffkeVP of Program Management & Chief of StaffN/AN/AN/A
Dr. Harald Murck M.D., Ph.D.VP of Clinical & Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Corporate governance

Aptinyx Inc.’s ISS governance QualityScore as of 1 May 2023 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.